NALIRIFOX Expands Options in First-Line Metastatic Pancreatic Cancer
Following the February 2024 FDA approval of irinotecan liposome (Onivyde) with oxaliplatin, fluorouracil, and leucovorin (NALIRIFOX), patients with…
Browsing Tag